Anticoagulation in percutaneous coronary intervention

Interventional Cardiology

Volumn 2, Issue 4, 2010, Pages 559-577

  O'Neill, Brian P ^a   Shaw, Eric Scot ^a   Cohen, Mauricio G ^b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

anticoagulant; coronary artery disease; percutaneous coronary intervention; thrombosis

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; ARGATROBAN; CLOPIDOGREL; DESULFATOHIRUDIN; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; M 118; OTAMIXABAN; RB 006; RB 007; RECOMBINANT NEMATODE ANTICOAGULANT PROTEIN C2; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTICOAGULATION; BLEEDING; BLOOD CLOT LYSIS; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG BINDING; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG SUBSTITUTION; HEART INFARCTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; LABORATORY TEST; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; THROMBOCYTOPENIA; THROMBOSIS; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

EID: 77956149373     PISSN: 17555302     EISSN: 17555310     Source Type: Journal    
DOI: 10.2217/ica.10.46     Document Type: Review

References (89)

1. Sianos G, Papafaklis MI, Daemen J et al.: Angiographic stent thrombosis after routine use of drug?eluting stents in ST?segment elevation myocardial infarction: the importance of thrombus burden. J. Am. Coll. Cardiol. 50, 573-583 (2007).
2. Singh M, Berger PB, Ting HH et al.: Infuence of coronary thrombus on outcome of percutaneous coronary angioplasty in the current era (the Mayo Clinic experience). Am. J. Cardiol. 88, 1091-1096 (2001).
3. Henriques JP, Zijlstra F, Ottervanger JP et al.: Incidence and clinical signifcance of distal embolization during primary angioplasty for acute myocardial infarction. Eur. Heart J. 23, 1112-1117 (2002).
4. Moscucci M, Fox KA, Cannon CP et al.: Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur. Heart J. 24, 1815-1823 (2003).
5. Kinnaird TD, Stabile E, Mintz GS et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am. J. Cardiol. 92, 930-935 (2003).
6. Mehran R, Pocock SJ, Stone GW et al.: Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non?ST?elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur. Heart J. 30, 1457-1466 (2009).
7. Lindsey JB, Marso SP, Pencina M et al.: Prognostic impact of periprocedural bleeding and myocardial infarction after percutaneous coronary intervention in unselected patients: results from the EVENT (Evaluation of Drug?Eluting Stents and Ischemic Events) registry. JACC Cardiovasc. Interv. 2, 1074-1082 (2009).
8. Alexander KP, Chen AY, Roe MT et al.: Anti?thrombotic strategy during percutaneous coronary intervention in NSTEMI: update from ACTION Registry?GWTG. J. Am. Coll. Cardiol. 53(Suppl. A), A398 (2009).
9. Linhardt RJ, Gunay NS: Production and chemical processing of low molecular weight heparins. Semin. Thromb. Hemost. 25(Suppl. 3), 5-16 (1999).
10. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI: Parenteral anticoagulants: American College of Chest Physicians Evidence?Based Clinical Practice Guidelines (8th edition). Chest 133, S141-S159 (2008).
11. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low?molecular?weight heparin and with a direct thrombin inhibitor. Circulation 9 7, 251-256 (1998).
12. Bahit MC, Topol EJ, Califf RM et al.: Reactivation of ischemic events in acute coronary syndromes: results from GUSTO? IIb. Gobal use of strategies to open occluded arteries in acute coronary syndromes. J. Am. Coll. Cardiol. 37, 1001-1007 (2001).
13. Kong DF, Hasselblad V, Harrington RA et al.: Meta?analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am. J. Cardiol. 92, 651-655 (2003).
14. Samama MM, Bara L, Gerotziafas GT: Mechanisms for the anti?thrombotic activity in man of low molecular weight heparins (LMWHs). Haemostasis 24, 105-117 (1994).
15. Weitz JI: Low-molecular-weight heparins. N. Engl. J. Med. 337, 688-698 (1997).
16. Warkentin TE, Levine MN, Hirsh J et al.: Heparin?induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330-1335 (1995).
17. Montalescot G, Bal-dit-Sollier C, Chibedi D et al.: Comparison of effects on markers of blood cell activation of enoxaparin, dalteparin, and unfractionated heparin in patients with unstable angina pectoris or non?ST?segment elevation acute myocardial infarction (the ARMADA study). Am. J. Cardiol. 91, 925-930 (2003).
18. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1?year follow?up of TIMI 1 1B and ESSENCE. Eur. Heart J. 23, 308-314 (2002).
19. Rabah MM, Premmereur J, Graham M et al.: Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris. Am. J. Cardiol. 84, 1391-1395 (1999).
20. Madan M, Radhakrishnan S, Reis M et al.: Comparison of enoxaparin versus heparin during elective percutaneous coronary intervention performed with either eptifbatide or tirofban (the ACTION trial). Am. J. Cardiol. 95, 1295-1301 (2005).
21. Bhatt DL, Lee BI, Casterella PJ et al.: Safety of concomitant therapy with eptifbatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single Bolus Enoxaparin Study. J. Am. Coll. Cardiol. 41, 20-25 (2003).
22. Kereiakes DJ, Grines C, Fry E et al.: Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention. J. Invasive Cardiol. 13, 272-278 (2001).
23. Ferguson JJ, Antman EM, Bates ER et al.: Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: fnal results of the National Investigators Collaborating on Enoxaparin?3 (NICE?3) study. Am. Heart J. 146, 628-634 (2003).
24. Ferguson JJ, Califf RM, Antman EM et al.: Enoxaparin vs unfractionated heparin in high?risk patients with non?ST?segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292, 45-54 (2004).
25. White HD, Kleiman NS, Mahaffey KW et al.: Effcacy and safety of enoxaparin compared with unfractionated heparin in high?risk patients with non?ST?segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am. Heart J. 152, 1042-1050 (2006).
26. Dumaine R, Borentain M, Bertel O et al.: Intravenous low?molecular?weight heparins compared with unfractionated heparin in percutaneous coronary intervention: quantitative review of randomized trials. Arch. Intern. Med. 167, 2423-2430 (2007).
27. Popma J J, Berger P, Ohman EM, Harrington RA, Grines C, Weitz JI: Anti?thrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Anti?thrombotic and Thrombolytic Therapy. Chest 126, 576S-599S (2004).
28. Montalescot G, White HD, Gallo R et al.: Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N. Engl. J. Med. 355, 1006-1017 (2006).
29. LaPointe NM, Chen AY, Alexander KP et al.: Enoxaparin dosing and associated risk of in?hospital bleeding and death in patients with non ST?segment elevation acute coronary syndromes. Arch. Intern. Med. 167, 1539-1544 (2007).
30. Anderson JL, Adams CD, Antman EM et al.: ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST?elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST?Elevation Myocardial Infarction):
31. Furie B, Furie BC: Molecular and cellular biology of blood coagulation. N. Engl. J. Med. 326, 800-806 (1992).
32. Di Nisio M, Middeldorp S, Buller HR: Direct thrombin inhibitors. N. Engl. J. Med. 353, 1028-1040 (2005).
33. Eitzman DT, Chi L, Saggin L, Schwartz RS, Lucchesi BR, Fay WP: Heparin neutralization by platelet?rich thrombi. Role of platelet Factor 4. Circulation 89, 1523-1529 (1994).
34. Direct Thrombin Inhibitor Trialists' Collaborative Group: Direct thrombin inhibitors in acute coronary syndromes: principal results of a meta?analysis based on individual patients' data. Lancet 359, 294-302 (2002).
35. Bittl JA, Strony J, Brinker JA et al.: Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N. Engl. J. Med. 333, 764-769 (1995).
36. Lincoff AM, Kleiman NS, Kottke?Marchant K et al.: Bivalirudin with planned or provisional abciximab versus low?dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET). Am. Heart J. 143, 847-853 (2002).
37. Lincoff AM, Bittl JA, Harrington RA et al.: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE?2 randomized trial. JAMA 289, 853-863 (2003).
38. Kastrati A, Neumann FJ, Mehilli J et al.: Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N. Engl. J. Med. 359, 688-696 (2008).
39. Stone GW, McLaurin BT, Cox DA et al.: Bivalirudin for patients with acute coronary syndromes. N. Engl. J. Med. 355, 2203-2216 (2006).
40. Stone GW, Witzenbichler B, Guagliumi G et al.: Bivalirudin during primary PCI in acute myocardial infarction. N. Engl. J. Med. 358, 2218-2230 (2008).
41. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ: Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: fnal report reanalysis of the Bivalirudin Angioplasty Study. Am. Heart J. 142, 952-959 (2001).
42. Lincoff AM, Kleiman NS, Kereiakes DJ et al.: Long?term effcacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE?2 randomized trial. JAMA 292, 696-703 (2004).
43. Gurm HS, Smith DE, Chetcuti SJ et al.: Temporal trends, safety, and effcacy of bivalirudin in elective percutaneous coronary intervention: insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. J. Interv. Cardiol. 20, 197-203 (2007).
44. Rassen JA, Mittleman MA, Glynn RJ, Alan Brookhart M, Schneeweiss S: Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention. Eur. Heart J. 31, 561-572 (2010).
45. Samama MM, Gerotziafas GT: Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 109, 1-11 (2003).
46. Turpie AG, Gallus AS, Hoek JA: A synthetic pentasaccharide for the prevention of deep?vein thrombosis after total hip replacement. N. Engl. J. Med. 344, 619-625 (2001).
47. Mehta SR, Steg PG, Granger CB et al.: Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 111, 1390-1397 (2005).
48. Mehta SR, Boden WE, Eikelboom JW et al.: Anti-thrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST-and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. Circulation 118, 2038-2046 (2008).
49. Montalescot G, Walenga JM: Catheter? related thrombosis: biological and clinical evidence for risk with currently available anticoagulants. Clin. Appl. Thromb. Hemost. 15, 183-196 (2009).
50. Paccaly A, Frick A, Rohatagi S et al.: Pharmacokinetics of otamixaban, a direct Factor Xa inhibitor, in healthy male subjects: pharmacokinetic model development for Phase II/III simulation of exposure. J. Clin. Pharmacol. 46, 37-44 (2006).
51. Cohen M, Bhatt DL, Alexander JH et al.: Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct Factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA?PCI trial. Circulation 115, 2642-2651 (2007).
52. Sabatine MS, Antman EM, Widimsky P et al.: Otamixaban for the treatment of patients with non?ST?elevation acute coronary syndromes (SEPIA?ACS1 TIMI 42): a randomised, double?blind, active?controlled, Phase II trial. Lancet 374, 787-795 (2009).
53. Giugliano R P, White JA, Bode C et al.: Early versus delayed, provisional eptifbatide in acute coronary syndromes. N. Engl. J. Med. 360, 2176-2190 (2009).
54. Alexander JH, Dyke CK, Yang H et al.: Initial experience with Factor?Xa inhibition in percutaneous coronary intervention: the XaNADU?PCI Pilot. J. Thromb. Haemost. 2, 234-241 (2004).
55. Volovyk Z, Monroe DM, Qi Y, Becker R, Hoffman M: A rationally designed heparin, M118, has anticoagulant activity similar to unfractionated heparin and different from Lovenox in a cell?based model of thrombin generation. J. Thromb. 28, 132-139 (2009).
56. Rao SV: Evaluation of a novel, rationally designed, low?molecular?weight heparin during elective PCI: results of the Phase II EMINENCE trial. Presented at: Transcatheter Therapeutics (TCT) Conference 2009. CA, USA, 21-25 September 2009.
57. Moons AH, Peters RJ, Bijsterveld NR et al.: Recombinant nematode anticoagulant protein c2, an inhibitor of the tissue factor/Factor VIIa complex, in patients undergoing elective coronary angioplasty. J. Am. Coll. Cardiol. 41, 2147-2153 (2003).
58. Giugliano R P, Wiviott SD, Stone PH et al.: Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial. J. Am. Coll. Cardiol. 49, 2398-2407 (2007).
59. Hoffman M, Monroe DM: Coagulation 2006: a modern view of hemostasis. Hematol. Oncol. Clin. North Am. 21, 1-11 (2007).
60. Becker RC, Povsic T, Cohen MG, Rusconi CP, Sullenger B: Nucleic acid aptamers as anti?thrombotic agents: opportunities in extracellular therapeutics. Thromb. Haemost. 103, 586-595 (2010).
61. Montalescot G, Collet JP, Tanguy ML et al.: Anti?Xa activity relates to survival and effcacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 110, 392-398 (2004).
62. Martin JL, Fry ET, Sanderink GJ et al.: Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: the Pharmacokinetics of Enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc. Interv. 61, 163-170 (2004).
63. Drouet L, Bal dit Sollier C, Martin J: Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK?on to ENOXaparin (STACKENOX) study. Am. Heart J. 158, 177-184 (2009).
64. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11 A. The Thrombolysis in Myocardial Infarction (TIMI) 11A Trial Investigators. J. Am. Coll. Cardiol. 29, 1474-1482 (1997).
65. White HD, Chew DP, Hoekstra JW et al.: Safety and effcacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non?ST?segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J. Am. Coll. Cardiol. 51, 1734-1741 (2008).
66. Dangas GD, Lansky AJ, Brodie BR et al.: Predictors of acute, subacute and late stent thrombosis after acute MI primary angioplasty in the Horizons AMI trial. Presented at: American College of Cardiology 2009 Annual Scientifc Sessions. Orlando, FL, USA, 29-31 March 2009.
67. Waksman R, Wolfram RM, Torguson RL et al.: Switching from enoxaparin to bivalirudin in patients with acute coronary syndromes without ST?segment elevation who undergo percutaneous coronary intervention. Results from SWITCH-a multicenter clinical trial. J. Invasive Cardiol. 18, 370-375 (2006).
68. Dougherty KG, Gaos CM, Bush HS, Leachman DR, Ferguson JJ: Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet. Cardiovasc. Diagn. 26, 260-263 (1992).
69. Ferguson JJ: All ACTs are not created equal. Tex. Heart Inst. J. 19, 1-3 (1992).
70. Narins CR, Hillegass WB Jr, Nelson CL et al.: Relation between activated clotting time during angioplasty and abrupt closure. Circulation 93, 667-671 (1996).
71. Ferguson JJ, Dougherty KG, Gaos CM, Bush HS, Marsh KC, Leachman DR: Relation between procedural activated coagulation time and outcome after percutaneous transluminal coronary angioplasty. J. Am. Coll. Cardiol. 23, 1061-1065 (1994).
72. Brener SJ, Moliterno DJ, Lincoff AM, Steinhubl SR, Wolski KE, Topol EJ: Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 110, 994-998 (2004).
73. Smith SC Jr, Feldman TE, Hirshfeld JW Jr et al.: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to update 2001 guidelines for percutaneous coronary intervention). Circulation 113, E166-E286 (2006).
74. Henry TD, Satran D, Knox LL, Iacarella CL, Laxson DD, Antman EM: Are activated clotting times helpful in the management of anticoagulation with subcutaneous low? molecular?weight heparin? Am. Heart J. 142, 590-593 (2001).
75. Montalescot G, Cohen M, Salette G et al.: Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial. Eur. Heart J. 29, 462-471 (2008)
76. Moliterno DJ, Hermiller JB, Kereiakes DJ et al.: A novel point?of?care enoxaparin monitor for use during percutaneous coronary intervention. Results of the Evaluating Enoxaparin Clotting Times (ELECT) study. J. Am. Coll. Cardiol. 42, 1132-1139 (2003).
77. Silvain J, Beygui F, Ankri A et al.: Enoxaparin anticoagulation monitoring in the catheterization laboratory using a new bedside test. J. Am. Coll. Cardiol. 55, 617-625 (2010).
78. Nowak G: Clinical monitoring of hirudin and direct thrombin inhibitors. Semin. Thromb. Hemost. 27, 537-541 (2001).
79. Bittl JA, Ahmed WH: Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty. Am. J. Cardiol. 82, 50P-56P (1998).
80. Rao SV, Ou FS, Wang TY et al.: Trends in the prevalence and outcomes of radial and femoral approaches to percutaneous coronary intervention: a report from the National Cardiovascular Data Registry. JACC Cardiovasc. Interv. 1, 379-386 (2008).
81. Manoukian SV, Feit F, Mehran R et al.: Impact of major bleeding on 30?day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J. Am. Coll. Cardiol. 49, 1362-1368 (2007).
82. Jolly SS, Amlani S, Hamon M, Yusuf S, Mehta SR: Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta?analysis of randomized trials. Am. Heart J. 157, 132-140 (2009).
83. Hamon M, Rasmussen LH, Manoukian SV et al.: Choice of arterial access site and outcomes in patients with acute coronary syndromes managed with an early invasive strategy: the ACUITY trial. EuroIntervention 5, 115-120 (2009).
84. Bertrand OF, Rodes?Cabau J, Rinfret S et al.: Impact of fnal activated clotting time after transradial coronary stenting with maximal antiplatelet therapy. Am. J. Cardiol. 104, 1235-1240 (2009).
85. Chase AJ, Fretz EB, Warburton WP et al.: Association of the arterial access site at angioplasty with transfusion and mortality: the MORTAL study (Mortality Beneft Of Reduced Transfusion after Percutaneous Coronary Intervention via the Arm or Leg). Heart 94, 1019-1025 (2008).
86. Montalescot G, Ongen Z, Guindy R et al.: Predictors of outcome in patients undergoing PCI. Results of the RIVIERA study. Int. J. Cardiol. 129(3), 379-387 (2008).
87. Melloni C, Peterson ED, Chen AY et al.: Cockcroft-Gault versus modifcation of diet in renal disease: importance of glomerular fltration rate formula for classifcation of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. 51, 991-996 (2008).
88. Hirsh J, O'Donnell M, Eikelboom JW: Beyond unfractionated heparin and warfarin: current and future advances. Circulation 116, 552-560 (2007).
89. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354(14), 1464-1476 (2006).